Generic Mezofy Availability
Last updated on Jun 11, 2025.
Mezofy is a brand name of aripiprazole, approved by the FDA in the following formulation(s):
MEZOFY (aripiprazole - film;oral)
-
Manufacturer: CMG PHARM CO LTD
Approval date: April 15, 2025
Strength(s): 5MG [RLD], 10MG [RLD], 15MG [RLD]
Is there a generic version of Mezofy available?
No. There is currently no therapeutically equivalent version of Mezofy available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mezofy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Fast-dissolving oral film preparation comprising aripiprazole
Patent 9,694,008
Issued: July 4, 2017
Inventor(s): Kim; Yong Soo et al.
Assignee(s): CMG Pharmaceutical Co., LTD. (Seoul, KR)The present invention relates to an orally fast dissolving film formulation including aripiprazole. The orally fast dissolving film formulation includes aripiprazole or a pharmaceutically acceptable salt thereof and an organic acid. The orally fast dissolving film formulation has a pH in the range of 4.7 to 6.0. The orally fast dissolving film formulation may further include a film base polymer. The orally fast dissolving film formulation has a high dissolution rate, causes no risk of damage to oral tissues, masks a bitter taste of aripiprazole, and gives a good feeling upon taking.
Patent expiration dates:
- August 7, 2033✓
- August 7, 2033
More about Mezofy (aripiprazole)
- Check interactions
- Compare alternatives
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: atypical antipsychotics
- Breastfeeding
Patient resources
Other brands
Abilify, Abilify Maintena, Aristada, Abilify Asimtufii, ... +3 more
Professional resources
Other brands
Abilify, Abilify Maintena, Aristada, Abilify Asimtufii, ... +3 more
Related treatment guides
Related/similar drugs
Abilify
Abilify (aripiprazole) is an antipsychotic medication used to treat schizophrenia, bipolar I ...
Seroquel
Seroquel is used to treat the symptoms of schizophrenia, bipolar disorder and major depressive ...
Vraylar
Vraylar is a once a day antipsychotic medication used to treat mental health or mood disorders ...
Zyprexa
Zyprexa (olanzapine) is an atypical antipsychotic that may be used to treat adults and adolescents ...
Latuda
Latuda information from Drugs.com, includes Latuda side effects, interactions and indications.
Rexulti
Rexulti is an antipsychotic used to treat major depressive disorder, schizophrenia, or agitation ...
Risperdal
Risperdal is used to treat schizophrenia and symptoms of bipolar disorder. Learn about side ...
Lurasidone
Lurasidone is used for bipolar disorder, borderline personality disorder, schizoaffective disorder ...
Risperidone
Risperidone is used to treat schizophrenia and symptoms of bipolar disorder. Learn about side ...
Olanzapine
Olanzapine (brand name Zyprexa) is an atypical antipsychotic that may be used to treat adults and ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.